Targets › MUC1
10 programs from 7 companies in 17 trials: 14 Phase 1, 3 Phase 2; Oncology; next expected readout Dec 2026.
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. (UniProt, P15941)
Open in Phaseline: the race on MUC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | MUC1 Peptide-Poly-ICLC Vaccine MUC1 peptide vaccine with poly-ICLC adjuvant for immunotherapy | MUC1 | Phase 2 | Colorectal Adenoma; Lung Carcinoma | Dec 2026 |
| National Cancer Institute (NCI) | Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5 Therapeutic cancer vaccine expressing CEA, MUC1, and Brachyury tumor-associated antigens | CEA, MUC1, TBXT | Phase 2 | Colorectal Carcinoma | Jul 2027 |
| National Cancer Institute (NCI) | Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1 | CEA, BRACHYURY, MUC1, KLK3, TBXT | Phase 2 | Adenocarcinoma; Metastatic Colorectal Cancer | Oct 2027 |
| Beijing Biotech | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) Allogeneic CAR-NK cells with dual-recognition CAR targeting MSLN and MUC1 | MSLN, MUC1 | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Feb 2027 |
| National Cancer Institute (NCI) | Falimarev (Fowlpox-CEA-MUC-1-TRICOM) Recombinant fowlpox virus expressing CEA and MUC-1 tumor-associated antigens with TRICOM c | CEA, MUC1 | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma | Apr 2027 |
| Finn, Olivera, PhD | MUC1 Peptide Vaccine Therapeutic vaccine targeting MUC1, a transmembrane glycoprotein in the mucin family, for | MUC1 | Phase 1 | Ductal Carcinoma in Situ | Feb 2028 |
| Olivera Finn | MUC1 100mer peptide vaccine MUC1 peptide vaccine with PolyICLC adjuvant | MUC1 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oct 2028 |
| NEOK Bio | NEOK002 EGFR and MUC1-targeting bispecific antibody-drug conjugate (ADC) | EGFR, MUC1 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Feb 2029 |
| Minerva Biotechnologies | huMNC2-CAR44 CAR T cells Anti-MUC1* (cleaved MUC1) CAR T cell therapy | MUC1 | Phase 1 | Metastatic Breast Cancer | Jan 2035 |
| Poseida Therapeutics | P-MUC1C-ALLO1 Allogeneic CAR-T cell therapy targeting MUC1-C | MUC1 | Phase 1 | Breast Cancer | Apr 2039 |
Pancreatic Ductal Adenocarcinoma (PDAC) (4) Locally Advanced Pancreatic Adenocarcinoma (2) Metastatic Breast Cancer (2) Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Ductal Carcinoma in Situ (1) Breast Cancer (1) Locally Advanced (Unresectable) or Metastatic Solid Tumors (1) Colorectal Adenoma (1) Lung Carcinoma (1) Non-small Cell Lung Cancer (NSCLC) (1) Colorectal Carcinoma (1)
mixed (5), other (3), protein or peptide (1), small molecule (1)
National Cancer Institute (NCI) (4) Finn, Olivera, PhD (1) Minerva Biotechnologies (1) Poseida Therapeutics (1) Beijing Biotech (1) NEOK Bio (1) Olivera Finn (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.